Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
- Disease/Condition
- Ischemic Stroke
- Drug/Device/Intervention
- Rivaroxaban 2.5 Mg Oral Tablet
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Brazilian Clinical Research Institute
- Phase
- Phase 4
- Start date
- Jul 01, 2024
- End date
- Dec 01, 2026
- Enrollment
- 4500 participants
Primary efficacy endpoint: Time to cardiovascular death, stroke, myocardial infarction (MI), or urgent arterial,Primary safety endpoint (rivaroxaban versus placebo): Time to major bleeding according to the International Society of Thrombosis and Hemostasis classification,Primary safety endpoint (colchicine versus placebo): Hospitalization for respiratory infections
The ARCHIMEDES study (Anti-inflammatory and anti-thRombotic therapy with colCHicine and low
 dose rIvaroxaban for Major adverse cardiovascular Events reDuction in ischEmic Stroke) will
 be a randomized, double-blind, 2x2 factorial clinical trial, which will include at least 3000
 and up to a maximum of 4500 patients with ischemic stroke without indication of oral
 anticoagulation.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06396858
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06396858 through Pure Global AI's free database. This Phase 4 trial is sponsored by Brazilian Clinical Research Institute and is currently Not yet recruiting. The study focuses on Ischemic Stroke. Target enrollment is 4500 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.